REGENERON PHARMACEUTICALS, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
REGENERON PHARMACEUTICALS, INC. (REGN) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits of $452.00 million as of 2025-12-31, per its 10-K filed 2026-02-04.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits · last filed 2026-02-04
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $452.00M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $419.70M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $413.60M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $416.20M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits as first filed |
|---|---|---|
| 2025-12-31 | $452.00M 10-K · filed 2026-02-04 | |
| 2024-12-31 | $419.70M 10-K · filed 2026-02-04 | |
| 2023-12-31 | $413.60M 10-K · filed 2025-02-05 | |
| 2022-12-31 | $416.20M 10-K · filed 2024-02-05 | |
| 2021-12-31 | $406.60M 10-K · filed 2023-02-06 | |
| 2020-12-31 | $436.60M 10-K · filed 2022-02-07 | |
| 2019-12-31 | $519.70M 10-K · filed 2021-02-08 | |
| 2018-12-31 | $458.20M 10-K · filed 2020-02-07 | |
| 2017-12-31 | $391.00M 10-K · filed 2019-02-07 | $391.03M 10-K · filed 2018-02-08 |
| 2016-12-31 | $515.98M 10-K · filed 2018-02-08 | |
| 2015-12-31 | $349.51M 10-K · filed 2017-02-09 | |
| 2014-12-31 | $216.64M 10-K · filed 2016-02-11 | $194.49M 10-K · filed 2015-02-12 |
| 2013-12-31 | $109.72M 10-K · filed 2015-02-12 | |
| 2012-12-31 | $53.37M 10-K · filed 2014-02-13 | |
| 2011-12-31 | $47.09M 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |